Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 13/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005436 | 0.97 | IL23R (0.45) | IL23RCXCR4 | |
| SCHEMBL31236827 | 0.96 | IL23R (0.42) | IL23RCXCR4 | |
| SCHEMBL30782822 | 0.94 | IL23R (0.45) | IL23RCXCR4 | |
| SCHEMBL30577893 | 0.93 | IL23R (0.47) | IL23R | |
| SCHEMBL22807693 | 0.92 | OPRL1 (0.46) | IL23RCXCR4 | |
| SCHEMBL22807629 | 0.92 | OPRL1 (0.46) | IL23RCXCR4 | |
| SCHEMBL22807630 | 0.92 | OPRL1 (0.46) | IL23RCXCR4 | |
| SCHEMBL31737829 | 0.91 | CXCR4 (0.44) | IL23RCXCR4 | |
| SCHEMBL29374718 | 0.89 | TFPI (0.44) | IL23RCXCR4 | |
| SCHEMBL31737509 | 0.89 | IL23R (0.45) | IL23RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222121-A1 | MULTIVALENT SMAC/DIABLO PROTEIN PEPTIDOMIMETIC COVALENTLY LINKED TO A TUMOR-HOMING PEPTIDE FOR TREATING CANCERS | BIOXEL INC. (US) | 2025-07-10 | — | — | US | claimed |
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | BIOXEL INC. (US) | 2025-07-03 | — | — | US | claimed |
| CN-117695408-A | Drug delivery nano-carrier and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2024-03-15 | — | — | CN | claimed |
| US-20250222121-A1 | MULTIVALENT SMAC/DIABLO PROTEIN PEPTIDOMIMETIC COVALENTLY LINKED TO A TUMOR-HOMING PEPTIDE FOR TREATING CANCERS | BIOXEL INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | BIOXEL INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-20240335548-A1 | MACROMOLECULES | STARPHARMA PTY LTD (AU) | 2024-10-10 | — | — | US | disclosed |
| CN-117695408-A | Drug delivery nano-carrier and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2024-03-15 | — | — | CN | disclosed |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | disclosed |
| CN-110124051-B | Macromolecules | 星法马私人有限公司 | 2022-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | PSMA6, PSMA1, CUL2 | IL23R 1958/4885CXCR4 2836/4885 |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | IL23R 1657/4885CXCR4 840/4885 |
| US-20250222121-A1 | MULTIVALENT SMAC/DIABLO PROTEIN PEPTIDOMIMETIC COVALENTLY LINKED TO A TUMOR-HOMING PEPTIDE FOR TREATING CANCERS | BIRC2, BIRC3, BIRC7 | IL23R 1587/4885CXCR4 206/4885 |
| US-20240335548-A1 | MACROMOLECULES | BRDT, CD44, EPCAM | IL23R 1587/4885CXCR4 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.